Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Shanghai Zelgen Pharma Tech Co. Ltd. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is handled by 1 distinct examiner, WEDDINGTON, KEVIN E. As the busiest examiner, WEDDINGTON, KEVIN E is responsible for 1 pending office action, the only one in the portfolio.
The portfolio is concentrated in 1 distinct art unit, reflecting a specific focus on pharmaceutical sciences. With 1 pending office action, the company's current engagement with the USPTO is limited to a single point of contact. The reliance on 1 distinct examiner means that the prosecution strategy should be tailored to the specific tendencies of WEDDINGTON, KEVIN E.
This lack of examiner diversity simplifies the management of the 1 pending action within the 1 art unit. Practitioners can focus exclusively on the procedural requirements and substantive preferences of the assigned examiner. The alignment of 1 distinct art unit with 1 distinct examiner confirms that the prosecution is not currently spread across different specialized groups, allowing for a more streamlined path toward allowance.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WEDDINGTON, KEVIN E | 1 | 75.3% | +9.8% |
| Art Unit | Apps |
|---|---|
| 1629 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18032930 | SUBSTITUTED BENZO OR PYRIDOPYRIMIDINE AMINE INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | WEDDINGTON, KEVIN E | 1629 | §112 | Non-Final OA | — | Pending | Oct 23, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialShanghai Zelgen Pharma Tech Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Kevin E Weddington has the most, with 1 of Shanghai Zelgen Pharma Tech Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
